Discover 4,047 paid clinical trials in Bronx, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 4,047
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Location: The Bronx NY, New York NY, Hackensack NJ, Morristown NJ,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT06881784
Phase 3, Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
for
Relapsed/Refractory Multiple Myeloma
Location: The Bronx NY, Boston MA, Chapel Hill NC, Chicago IL,
Sponsor: Ichnos Sciences SA
Sex: All
Age: 18+
Code: NCT05862012
Phase 1, Recruiting
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
for
Systemic Lupus Erythematosus of Childhood (Disorder)
Location: The Bronx NY, Toronto, Cincinnati OH, Grand Rapids MI,
Sponsor: Michigan State University
Sex: All
Age: 12 - 22
Code: NCT06232304
Recruiting
Biological Allograft Chain Tissue Implant
for
Vertebral Body Compression Fracture(s)
Location: Bronx NY, New York NY, Manhasset NY, Denver CO
Sponsor: Lenoss Medical
Sex: All
Age: 50+
Code: NCT04064710
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
for
Multiple Myeloma
Location: The Bronx NY, New York NY, Hackensack NJ,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05201781
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
for
Ischemic Stroke, Intracerebral Hemorrhage,
Location: The Bronx NY, New York NY, Philadelphia PA, Boston MA,
Sponsor: Massachusetts General Hospital
Sex: All
Age: 18+
Code: NCT04916210
Recruiting
Digoxin Medulloblastoma Study
for
Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Location: The Bronx NY, Hartford CT, Baltimore MD,
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All
Age: 1 - 30
Code: NCT06701812
Phase 2, Recruiting
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue